IMPL

Impel NeuroPharma, Inc. [IMPL] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IMPL Stock Summary

In the News

08:14 28 Mar 2024 IMPL

Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?

Impel Pharmaceuticals (NASDAQ: IMPL ) stock is on the rise Friday after the company announced an amended credit agreement with Oaktree Fund Administration. This new credit agreement has Impel Pharmaceuticals obtaining a loan of $121.5 million from new and existing investors.

08:50 28 Mar 2024 IMPL

Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?

Impel Pharmaceuticals (NASDAQ: IMPL ) stock is falling on Wednesday after the biopharmaceutical company failed to file its earnings report on time. According to a filing with the Securities and Exchange Commission (SEC), several issues kept Impel Pharmaceuticals from filing in a timely manner.

08:00 28 Mar 2024 IMPL

Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society

Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa

08:00 28 Mar 2024 IMPL

Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update.

03:20 28 Mar 2024 IMPL

Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript

Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q4 2022 Earnings Conference Call March 24, 2023 8:30 AM ET Company Participants Adrian Adams - Chairman & Chief Executive Officer Leonard Paolillo - Chief Commercial Officer Rajiv Amin - Controller & Interim Chief Financial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Laura Chico - Wedbush Sean Kim - JonesTrading Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings and Business Update Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.

11:27 28 Mar 2024 IMPL

Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 6.73% and 23.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

08:00 28 Mar 2024 IMPL

Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023

SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update.

04:01 28 Mar 2024 IMPL

Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March

SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming investor conferences in March:

01:24 28 Mar 2024 IMPL

Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcript

Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Operator Good morning, ladies and gentlemen, and welcome to Impel Pharmaceuticals Third Quarter 2022 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode.

10:33 28 Mar 2024 IMPL

Impel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call Transcript

Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard S. Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Laura Chico - Wedbush Eddie Hickman - Guggenheim Securities Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals' Second Quarter 2022 Earnings and Business Update Conference Call.

IMPL Financial details

Company Rating
Neutral
Market Cap
956K
Income
-96.11M
Revenue
20.99M
Book val./share
-3.87
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
160
Optionable
No
Shortable
Yes
Earnings
22 Mar 2024
P/E
-0.01
Forward P/E
0.05
PEG
0
P/S
0.05
P/B
-0.01
P/C
4
P/FCF
-0.01
Quick Ratio
0.05
Current Ratio
0.19
Debt / Equity
-1.25
LT Debt / Equity
-0.02
-
-
EPS (TTM)
-4.05
EPS next Y
0.85
EPS next Q
1.58
EPS this Y
5.34%
EPS next Y
-120.99%
EPS next 5Y
-120.99%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-23.71%
EPS Q/Q
87.1%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
70.78%
Inst Trans
0.96%
ROA
-274%
ROE
133%
ROC
0.78%
Gross Margin
53%
Oper. Margin
-334%
Profit Margin
-458%
Payout
-
Shs Outstand
23.9M
Shs Float
7.99M
-
-
-
-
Target Price
-
52W Range
0.0212-4.2
52W High
-
52W Low
-
RSI
39
Rel Volume
0.7
Avg Volume
1.02M
Volume
720.03K
Perf Week
-60%
Perf Month
-91.18%
Perf Quarter
-
Perf Half Y
-92.75%
-
-
-
-
Beta
1.173
-
-
Volatility
0.02%, 0.14%
Prev Close
-60.44%
Price
0.04
Change
-50%

IMPL Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
000.050.54
Net income per share
-3.19-3.49-5.24-5.52
Operating cash flow per share
-2.78-2.98-4.55-3.99
Free cash flow per share
-2.89-3.12-4.57-4.05
Cash per share
2.820.546.042.59
Book value per share
-6.98-10.163.6-1.88
Tangible book value per share
-6.98-10.163.6-1.88
Share holders equity per share
-6.98-10.163.6-1.88
Interest debt per share
00.642.022.77
Market cap
197.08M197.08M126M87.92M
Enterprise value
160.08M198.4M67.24M78.45M
P/E ratio
-4.71-4.3-1.65-0.68
Price to sales ratio
00188.626.95
POCF ratio
-5.4-5.03-1.9-0.94
PFCF ratio
-5.19-4.81-1.89-0.93
P/B Ratio
-2.15-1.482.4-1.99
PTB ratio
-2.15-1.482.4-1.99
EV to sales
00100.666.2
Enterprise value over EBITDA
-3.92-4.48-0.94-0.94
EV to operating cash flow
-4.39-5.06-1.01-0.84
EV to free cash flow
-4.21-4.84-1.01-0.83
Earnings yield
-0.21-0.23-0.61-1.47
Free cash flow yield
-0.19-0.21-0.53-1.08
Debt to equity
0-0.060.56-1.16
Debt to assets
00.70.30.58
Net debt to EBITDA
0.91-0.030.820.11
Current ratio
4.750.785.933.6
Interest coverage
000-6.01
Income quality
0.870.860.870.88
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0076.26.16
Research and developement to revenue
0030.780.91
Intangibles to total assets
0000
Capex to operating cash flow
0.040.050.010.01
Capex to revenue
00-0.61-0.11
Capex to depreciation
-2.11-1.65-0.38-1.15
Stock based compensation to revenue
004.690.41
Graham number
22.3728.2320.615.3
ROIC
0.450.36-0.87-9.99
Return on tangible assets
-0.99-3.8-0.78-1.46
Graham Net
-7.38-10.533.1-2.66
Working capital
31.2M-2.35M78.62M57.65M
Tangible asset value
-91.7M-133.5M52.51M-44.16M
Net current asset value
-94.44M-137.39M49.17M-52.9M
Invested capital
0-0.060.56-1.16
Average receivables
0215K790.5K4.4M
Average payables
03.52M5.34M6.23M
Average inventory
0-215K1.3M5.63M
Days sales outstanding
00738.74214.75
Days payables outstanding
003.36K342.35
Days of inventory on hand
001.49K473.57
Receivables turnover
000.491.7
Payables turnover
000.111.07
Inventory turnover
000.240.77
ROE
0.460.34-1.462.93
Capex per share
-0.12-0.14-0.03-0.06

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.130.210.180.280.21
Net income per share
-1.73-1.53-1.63-0.31-0.58
Operating cash flow per share
-0.96-0.76-1.02-0.86-0.7
Free cash flow per share
-0.96-0.8-1.06-0.86-0.74
Cash per share
3.362.561.490.640.01
Book value per share
-0.94-1.86-3.07-3.33-3.87
Tangible book value per share
-0.94-1.86-3.07-3.33-3.87
Share holders equity per share
-0.94-1.86-3.07-3.33-3.87
Interest debt per share
1.992.872.12.084.68
Market cap
115.47M89.02M33.24M30.16M10.21M
Enterprise value
86.03M79.55M50.68M67.29M124.77M
P/E ratio
-0.7-0.61-0.22-1.02-0.18
Price to sales ratio
37.4617.787.64.582.03
POCF ratio
-5.09-4.95-1.38-1.48-0.62
PFCF ratio
-5.06-4.69-1.32-1.49-0.58
P/B Ratio
-5.18-2.02-0.46-0.38-0.11
PTB ratio
-5.18-2.02-0.46-0.38-0.11
EV to sales
27.9115.8911.5910.2224.84
Enterprise value over EBITDA
-4.05-4.36-2.36-4.18-9.74
EV to operating cash flow
-3.79-4.42-2.1-3.29-7.55
EV to free cash flow
-3.77-4.19-2.01-3.31-7.14
Earnings yield
-0.35-0.41-1.16-0.24-1.35
Free cash flow yield
-0.2-0.21-0.76-0.67-1.71
Debt to equity
-2.26-1.16-0.73-0.66-1.25
Debt to assets
0.480.580.821.173.27
Net debt to EBITDA
1.390.52-0.81-2.31-8.94
Current ratio
4.973.62.330.270.19
Interest coverage
6.65-1.077.835.343.5
Income quality
0.730.780.82.781.2
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
6.384.065.042.933.06
Research and developement to revenue
1.020.140.690.030.05
Intangibles to total assets
00000
Capex to operating cash flow
0.010.060.04-0.010.06
Capex to revenue
-0.05-0.2-0.240.02-0.19
Capex to depreciation
-0.51-3.31-3.85-2.32-1.51
Stock based compensation to revenue
0.180.250.30.170.21
Graham number
6.04810.64.827.12
ROIC
-0.9-2.831.941.02-0.46
Return on tangible assets
-0.39-0.41-0.6-0.16-0.39
Graham Net
-1.64-2.62-3.94-4.22-4.98
Working capital
79.31M57.65M29.6M-88.32M-101.32M
Tangible asset value
-22.29M-44.16M-72.91M-79.16M-91.91M
Net current asset value
-28.19M-52.9M-85.75M-91.06M-103.55M
Invested capital
-2.26-1.16-0.73-0.66-1.25
Average receivables
5.47M6.79M6.86M6.55M6.7M
Average payables
4.75M5.42M6.11M4.8M3.6M
Average inventory
7.78M8.52M8.22M7.5M6.92M
Days sales outstanding
178.98133.78129.2893.14118.11
Days payables outstanding
283.55247.31241.5696.65150.7
Days of inventory on hand
514.58342.1315.65195.23277.02
Receivables turnover
0.50.670.70.970.76
Payables turnover
0.320.360.370.930.6
Inventory turnover
0.170.260.290.460.32
ROE
1.840.820.530.090.15
Capex per share
-0.01-0.04-0.040.01-0.04

IMPL Frequently Asked Questions

What is Impel NeuroPharma, Inc. stock symbol ?

Impel NeuroPharma, Inc. is a US stock , located in Seattle of Wa and trading under the symbol IMPL

What is Impel NeuroPharma, Inc. stock quote today ?

Impel NeuroPharma, Inc. stock price is $0.04 today.

Is Impel NeuroPharma, Inc. stock public?

Yes, Impel NeuroPharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap